Canaccord raised the firm’s price target on Privia Health (PRVA) to $34 from $32 and keeps a Buy rating on the shares. The firm said its thesis on the copany is playing out as the Q3 beat was strong across the board and management noted that 3Q capitated results would likely be the high-water mark for 2025 as there was retroactive timing of data that contributed to the strength.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA: